by DrKSSMDPhD | December 2, 2017 2:01 pm
This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.
Source URL: https://www.stockgumshoe.com/2017/12/special-comment-update-from-arth-ceo-terrence-norchi-md-mba/
Copyright ©2024 Stock Gumshoe unless otherwise noted.
$MGEN
Nine of fourteen (64%) of patients treated for more than one month showed a 50% or greater improvement in total skin disease
Seven patients have achieved at least a 50% improvement that has been durable for at least four months
MRG-106 continued to be generally well-tolerated at all dose levels evaluated as of December 4, 2017
Initiated dosing in three additional oncology indications including chronic lymphocytic leukemia, diffuse large B-cell lymphoma and adult T-cell leukemia/lymphoma within the ongoing MRG-106 Phase 1 trial
$akao – Achaogen Appoints Blake Wise Chief Executive Officer
– Dr. Kenneth Hillan to become President, R&D –
– Succession designed to lead Achaogen through next phase of growth as a commercial-stage company –
– Transition effective January 1, 2018 –
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) — Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that Blake Wise, currently Achaogen’s President and Chief Operating Officer, will succeed Kenneth Hillan, M.B. Ch.B., as Chief Executive Officer effective January 1, 2018. At the same time, Dr. Hillan will take on the newly created role of President, R&D (and President of Achaogen). Dr. Hillan will remain on, and Mr. Wise will join, the Company’s Board of Directors.
“Achaogen is preparing for approval of its first drug, plazomicin, and Blake’s experience scaling and leading commercial organizations is perfectly suited to maximizing this stage of growth, and value, of the Company. At the same time, we are extremely fortunate to have Kenneth in a role that fully leverages his passion and success at the intersection of preclinical research and clinical drug development,” said Bryan Roberts, Chairman of Achaogen’s Board of Directors and a partner at the venture capital firm Venrock. “I cannot think of two more collaborative and complementary individuals to continue to shepherd great science, products and people towards making meaningful differences to patients.”
“It will be an honor to lead Achaogen forward as its new CEO. The fundamentals of the company are strong – as is our future – and I look forward to continuing to build an enduring organization that adds value to patients, employees and stockholders,” said Wise. “Kenneth has successfully established scientific rigor and incredibly talented teams across Achaogen, and I am similarly committed to following the science while making a valuable impact on patient health. I am beyond appreciative of Kenneth’s leadership and contributions to Achaogen, and I am excited to continue our work together to achieve our mission to create a leading antibacterial company addressing the significant threat posed by antimicrobial resistance.”
Mr. Wise joined Achaogen as Chief Operating Officer in 2015 and, in February 2017, he was also appointed President. Prior to Achaogen, Mr. Wise spent 13 years at Genentech, where he served in multiple leadership positions of increasing responsibility, including establishing and leading Genentech’s Cross BioOncology franchise.
“As we set our sights toward the potential launch of plazomicin, I am confident that this transition is absolutely the right move for Achaogen and for me, and I look forward to continuing to work with the extraordinarily talented team at Achaogen in my new role,” said Dr. Hillan. “Working at Achaogen is incredibly rewarding, and since R&D is my passion, I now intend to focus on advancing and deepening our pipeline, with the goal of helping Blake to build Achaogen as a leader in the biotechnology industry.”
$AUPH fp – Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index
Click here to read the full article https://ir.auriniapharma.com/press-releases/detail/103
$APTO xxowxx – Aptose Biosciences, Inc. has added a news release to its Investor Relations website.
Title: OHSU and Aptose Present CG’806 Preclinical Data at ASH 59th Annual Meeting
Title: Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting
A form 6-K regarding Aptose Biosciences, Inc. has been filed with the United States Securities and Exchange Commission.
Date(s): 11-Dec-2017 4:05 PM
For a complete listing of our news releases, please click here http://phx.corporate-ir.net/phoenix.zhtml?c=116148&p=irol-sec
$FATE long – Fate Therapeutics Announces Successful Completion Of Technology Transfer And Initiation Of IND-Enabling Manufacture Of FT500 http://ir.fatetherapeutics.com/releasedetail.cfm?ReleaseID=1051450
$FATE $AFMD
Congratulations Ben for winning the horse race with FATE against AFMD. Fortunately I exited the latter just in time.
Best,
Helen
What was the news about AFMD? I still hold the stock.
I dialed up on TWITTER …..ASH conference and it’s all about CAR-T.
#NEW THREAD $APTO ow – https://www.stockgumshoe.com/2017/12/is-a-misperception-subduing-share-price-at-aptose-apto/ Best2ALL! 🙂
$ARTH If I am not reading too much into this it sounds like good news for clas ii devices 510 filings early 2018;
https://blogs.fda.gov/fdavoice/index.php/2017/12/advancing-policies-to-promote-safe-effective-medtech-innovation/
Please join the #Gummune on the #NEW THREAD $APTO ow – https://www.stockgumshoe.com/2017/12/is-a-misperception-subduing-share-price-at-aptose-apto/ Best2ALL!
Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA…ouch
https://finance.yahoo.com/news/arch-therapeutics-withdraws-510-k-125000205.html